Atty Dkt. No.: STAN-316 USSN: 10/528,377

AMENDMENTS TO THE CLAIMS:

1. (Currently amended) A method comprising:

 $contacting \ a \ hepatitis \ C \ virus \ (HCV) \ NS4B \ nucleotide \ binding \ motif \ (NBM) \ polypeptide$ with a candidate agent; and

determining an effect of said candidate agent on a GTPase activity of said polypeptide;

determining an effect of said candidate agent on replication of HCV.

2. (Canceled)

and

- 3. (Previously presented) The method of claim 1, wherein said method further comprises determining an effect of said candidate agent on nucleotide binding of said polypeptide.
 - 4. (Canceled)
- 5. (Previously presented) The method of claim 1, wherein said method further comprises determining an effect of said candidate agent on RNA binding of said polypeptide.
 - 6. (Original) The method of claim 1, wherein said candidate agent is a nucleotide analog.
- 7. (Original) The method of claim 6, wherein said nucleotide analog is a non-hydrolysable nucleotide.
 - 8. (Canceled).
- 9. (**Currently amended**) The method of <u>claim 1</u> <u>claim 8</u>, wherein said HCV is a subgenomic or full length HCV replicon.

Atty Dkt. No.: STAN-316 USSN: 10/528,377

10. (Currently amended) The method of <u>claim 1</u> <u>claim 8</u>, <u>further comprising</u> <u>wherein said</u> <u>method comprises determining an effect of said candidate agent on testing</u> HCV replication in a huh7 cell.

11-21. (Canceled)

- 22. (**Currently Amended**) The method of <u>claim 1 elaim 8</u>, wherein said method comprises assaying said candidate agent on HCV replication in a liver cell line or primary liver cell.
- 23. **(Currently Amended)** The method of claim 9, wherein <u>said aid-</u>HCV is live virus or a replicon thereof.